1. Home
  2. OPRX vs YARW Comparison

OPRX vs YARW Comparison

Compare OPRX & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimizeRx Corporation

OPRX

OptimizeRx Corporation

N/A

Current Price

$7.68

Market Cap

167.1M

ML Signal

N/A

Logo Yarrow Bioscience Inc. Common Stock

YARW

Yarrow Bioscience Inc. Common Stock

N/A

Current Price

$18.88

Market Cap

154.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPRX
YARW
Founded
2006
2021
Country
United States
United States
Employees
105
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.1M
154.5M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
OPRX
YARW
Price
$7.68
$18.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
4
Target Price
$12.30
★ $57.33
AVG Volume (30 Days)
★ 181.3K
173.9K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 124.55
33.33
EPS
★ N/A
N/A
Revenue
★ $109,429,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.01
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 18.78
N/A
52 Week Low
$4.54
$12.39
52 Week High
$15.59
$44.28

Technical Indicators

Market Signals
Indicator
OPRX
YARW
Relative Strength Index (RSI) 37.22 48.63
Support Level $7.23 $18.05
Resistance Level $8.30 $20.57
Average True Range (ATR) 0.69 2.44
MACD -0.19 0.46
Stochastic Oscillator 38.21 77.19

Price Performance

Historical Comparison
OPRX
YARW

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

About YARW Yarrow Bioscience Inc. Common Stock

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.

Share on Social Networks: